The primary objective is to investigate the pharmacokinetics (PK) of 2 doses of alfuzosin (given as a solution or tablets depending on age) in children and adolescents 2 to 16 years of age with elevated detrusor Leak Point Pressure (LPP) (≥40 cm H2O) of neuropathic etiology stratified into 2 age groups (2 to 7 years and 8 to 16 years). The secondary objectives are to investigate the safety and tolerability of the 2 dose regimens and to determine the effect of the 2 dose regimens on detrusor LPP.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
29
Sanofi-Aventis Administrative Office
Malvern, Pennsylvania, United States
Sanofi-Aventis Administrative Office
Belgrade, Serbia
PK parameters
Safety evaluation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.